<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02793856</url>
  </required_header>
  <id_info>
    <org_study_id>MHC001</org_study_id>
    <nct_id>NCT02793856</nct_id>
  </id_info>
  <brief_title>PD-1 Knockout Engineered T Cells for Metastatic Non-small Cell Lung Cancer</brief_title>
  <official_title>A Dose-escalation Phase I Trial of PD-1 Knockout Engineered T Cells for the Treatment of Metastatic Non-small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sichuan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chengdu MedGenCell, Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sichuan University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety of PD-1 knockout engineered T cells in treating
      metastatic non-small cell lung cancer. Blood samples will also be collected for research
      purposes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a dose-escalation study of ex-vivo knocked-out, expanded, and selected PD-1
      knockout-T cells from autologous origin. Patients are assigned to 1 of 3 treatment groups to
      determine the maximal tolerant dose. After the lower number of cycles are considered
      tolerant, an arm of the next higher number of cycles will be open to next patients.
      Biomarkers and immunological markers are collected and analyzed as well.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 2016</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with Adverse Events and/or Dose Limiting Toxicities as a Measure of Safety and tolerability of dose of PD-1 Knockout T cells using Common Terminology Criteria for Adverse Events (CTCAE v4.0) in patients</measure>
    <time_frame>Dose Escalation - Approximately 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response Rate</measure>
    <time_frame>90 days</time_frame>
    <description>Response will be evaluated according to RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival - PFS</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to average 10 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival - OS</measure>
    <time_frame>The time from randomization to death from any cause, assessed up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peripheral blood circulating tumor DNA</measure>
    <time_frame>6 weeks</time_frame>
    <description>Peripheral circuiting tumor DNA is collected at baseline and 6 weeks after last treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Temporal Interleukin-2 change in the peripheral blood</measure>
    <time_frame>Baseline and 1 month and 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Temporal Interferon-γ change in the peripheral blood</measure>
    <time_frame>Baseline and 1 month and 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Temporal tumour necrosis factor-α change in the peripheral blood</measure>
    <time_frame>Baseline and 1 month and 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Temporal Interleukin-6 change in the peripheral blood</measure>
    <time_frame>Baseline and 1 month and 3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Metastatic Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>A - Two cycles</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Peripheral blood lymphocytes will be collected and Programmed cell death protein 1(PDCD1) gene will be knocked out by CRISPR Cas9 in the laboratory (PD-1 Knockout T cells). The lymphocytes will be selected and expanded ex vivo and infused back into patients. Cyclophosphamide at 20mg/kg single dose will be administered 3 days i.v. before cell infusion.
A total of 1 x 10^7/kg PD-1 Knockout T cells will be infused in one cycle. Each cycle is divided into three administrations, with 20% infused in the first administration, 30% in the second, and the remaining 50% in the third. Patients will receive a total of two cycles of treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B- Two cycles</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Peripheral blood lymphocytes will be collected and Programmed cell death protein 1(PDCD1) gene will be knocked out by CRISPR Cas9 in the laboratory (PD-1 Knockout T cells). The lymphocytes will be selected and expanded ex vivo and infused back into patients. Cyclophosphamide at 20mg/kg single dose will be administered 3 days i.v. before cell infusion.
A total of 2 x 10^7/kg PD-1 Knockout T cells will be infused in one cycle. Each cycle is divided into three administrations, with 20% infused in the first administration, 30% in the second, and the remaining 50% in the third. Patients will receive a total of two cycles of treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C- Two cycles</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Peripheral blood lymphocytes will be collected and Programmed cell death protein 1(PDCD1) gene will be knocked out by CRISPR Cas9 in the laboratory (PD-1 Knockout T cells). The lymphocytes will be selected and expanded ex vivo and infused back into patients. Cyclophosphamide at 20mg/kg single dose will be administered 3 days i.v. before cell infusion.
A total of 4 x 10^7/kg PD-1 Knockout T cells will be infused in one cycle. Each cycle is divided into three administrations, with 20% infused in the first administration, 30% in the second, and the remaining 50% in the third. Patients will receive a total of two cycles of treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>To deplete Tregs before collecting peripheral blood</description>
    <arm_group_label>A - Two cycles</arm_group_label>
    <arm_group_label>B- Two cycles</arm_group_label>
    <arm_group_label>C- Two cycles</arm_group_label>
    <other_name>Cytoxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>PD-1 Knockout T Cells</intervention_name>
    <description>Autologous lymphocytes are collected and PDCD1 gene is knocked out in the laboratory. Cells are selected and expanded ex vivo. Cells are infused back to the patients for treatment</description>
    <arm_group_label>A - Two cycles</arm_group_label>
    <arm_group_label>B- Two cycles</arm_group_label>
    <arm_group_label>C- Two cycles</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pathologically verified stage IV non-small cell lung cancer with measurable lesions
             (On CT: longest diameter of tumoral lesion &gt;=10 mm, shorted diameter of lymph node
             &gt;=15 mm; measurable lesions should not have been irradiated)

          -  Progressed after all standard treatment

          -  Performance score: 0-1

          -  Expected life span: &gt;= 6 months

          -  Toxicities from prior treatment has resolved. Washout period is 4 weeks for
             chemotherapy, and 2 weeks for targeted therapy

          -  Major organs function normally

          -  Women at pregnant ages should be under contraception

          -  Willing and able to provide informed consent

        Exclusion Criteria:

          -  Pathology is mixed type

          -  Emergent treatment of tumor emergency is needed

          -  Poor vasculature

          -  Coagulopathy, or ongoing thrombolytics and/or anticoagulation

          -  Blood-borne infectious disease, e.g. hepatitis B

          -  History of mandatory custody because of psychosis or other psychological disease
             inappropriate for treatment deemed by treating physician

          -  With other immune diseases, or chronic use of immunosuppressants or steroids

          -  Compliance cannot be expected

          -  Other conditions requiring exclusion deemed by physician
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>You Lu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sichuan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>You Lu, MD</last_name>
    <phone>0086-28-85423571</phone>
    <email>radyoulu@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xiaojuan Zhou, MD</last_name>
    <phone>0086-28-85423571</phone>
    <email>zhouxiaojuan765@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>West China Hospital, Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>You Lu, MD</last_name>
      <phone>00862885423571</phone>
      <email>radyoulu@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Xiaojuan Zhou</last_name>
      <phone>00862885423571</phone>
      <email>zhouxiaojuan765@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Lei Deng, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L, Carcereny E, Ahn MJ, Felip E, Lee JS, Hellmann MD, Hamid O, Goldman JW, Soria JC, Dolled-Filhart M, Rutledge RZ, Zhang J, Lunceford JK, Rangwala R, Lubiniecki GM, Roach C, Emancipator K, Gandhi L; KEYNOTE-001 Investigators. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015 May 21;372(21):2018-28. doi: 10.1056/NEJMoa1501824. Epub 2015 Apr 19.</citation>
    <PMID>25891174</PMID>
  </reference>
  <reference>
    <citation>Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, Waterhouse D, Ready N, Gainor J, Arén Frontera O, Havel L, Steins M, Garassino MC, Aerts JG, Domine M, Paz-Ares L, Reck M, Baudelet C, Harbison CT, Lestini B, Spigel DR. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med. 2015 Jul 9;373(2):123-35. doi: 10.1056/NEJMoa1504627. Epub 2015 May 31.</citation>
    <PMID>26028407</PMID>
  </reference>
  <reference>
    <citation>Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, Barlesi F, Kohlhäufl M, Arrieta O, Burgio MA, Fayette J, Lena H, Poddubskaya E, Gerber DE, Gettinger SN, Rudin CM, Rizvi N, Crinò L, Blumenschein GR Jr, Antonia SJ, Dorange C, Harbison CT, Graf Finckenstein F, Brahmer JR. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med. 2015 Oct 22;373(17):1627-39. doi: 10.1056/NEJMoa1507643. Epub 2015 Sep 27.</citation>
    <PMID>26412456</PMID>
  </reference>
  <reference>
    <citation>Rosenberg SA, Restifo NP. Adoptive cell transfer as personalized immunotherapy for human cancer. Science. 2015 Apr 3;348(6230):62-8. doi: 10.1126/science.aaa4967. Review.</citation>
    <PMID>25838374</PMID>
  </reference>
  <reference>
    <citation>Sharma P, Allison JP. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell. 2015 Apr 9;161(2):205-14. doi: 10.1016/j.cell.2015.03.030. Review.</citation>
    <PMID>25860605</PMID>
  </reference>
  <reference>
    <citation>Niu Y, Shen B, Cui Y, Chen Y, Wang J, Wang L, Kang Y, Zhao X, Si W, Li W, Xiang AP, Zhou J, Guo X, Bi Y, Si C, Hu B, Dong G, Wang H, Zhou Z, Li T, Tan T, Pu X, Wang F, Ji S, Zhou Q, Huang X, Ji W, Sha J. Generation of gene-modified cynomolgus monkey via Cas9/RNA-mediated gene targeting in one-cell embryos. Cell. 2014 Feb 13;156(4):836-43. doi: 10.1016/j.cell.2014.01.027. Epub 2014 Jan 30.</citation>
    <PMID>24486104</PMID>
  </reference>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 30, 2016</study_first_submitted>
  <study_first_submitted_qc>June 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 8, 2016</study_first_posted>
  <last_update_submitted>December 26, 2017</last_update_submitted>
  <last_update_submitted_qc>December 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sichuan University</investigator_affiliation>
    <investigator_full_name>You Lu</investigator_full_name>
    <investigator_title>Chair of Department of Thoracic Cancer</investigator_title>
  </responsible_party>
  <keyword>lung cancer</keyword>
  <keyword>immune checkpoint</keyword>
  <keyword>PD-1</keyword>
  <keyword>CRISPER</keyword>
  <keyword>autologous cell infusion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

